Combination Radiopharmaceuticals in mCRPC Integrating the Latest Data Into Clinical Practice CME Austria Center Vienna Sunday, 18 October 2026 | 13:15 - 14:45 CEST

https://events.medscapelive.org/website/98392/?utm_campaign=461679.01a_hybrid_10-18&utm_source=mrk&utm_medium=em&utm_content=int Radiopharmaceutical combinations are reshaping how we manage metastatic castration-resistant prostate cancer (mCRPC). This 90-minute live town hall gathers a multidisciplinary panel of experts from the fields of nuclear medicine, medical and radiation oncology, and urology who will lay out what the emerging evidence for combination therapies can mean for your clinical practice. Together they will examine the latest clinical data, clarify updated guideline recommendations, offer practical strategies for treatment sequencing, and make the case for bone-protecting agents in early mCRPC care. Interactive polling and live Q&A keep the conversation grounded in real-world practice, and short patient documentaries provide a vital perspective into the lived patient experience.